Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Indications For Resistant Pathogens Could Rely On PK/PD – FDA

Executive Summary

Companies seeking an indication for an antimicrobial agent to treat resistant pathogens could rely mostly on pharmacokinetic and pharmacodynamic studies, FDA said

You may also be interested in...



Antibiotic Research Stalling In Conversion Of Target Into New Drug

Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7

Antibiotic Research Stalling In Conversion Of Target Into New Drug

Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7

Ertaczo Launch Could Help OrthoNeutrogena Rebuild Antifungal Market Share

OrthoNeutrogena's topical athlete's foot treatment Ertaczo gives the company a chance to recapture market share lost to generic versions of another one of its antifungals, Spectazole

Related Content

UsernamePublicRestriction

Register

PS040857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel